The CNT (CEP72, NUDT15, and TPMT) and NT (NUDT15 and TPMT) genotyping panels investigate all clinically relevant genetic variants in these actionable pharmacogenetics (PGx) genes in a single test. Rather than testing a limited number of variants in other platforms, our comprehensive panels yield thorough dosing guidelines for thiopurines and vincristine with higher accuracy.
TPMT and NUDT15 are two important PGx genes recommended in the latest CPIC guidelines to guide proper dosing of thiopurines, including azathioprine, mercaptopurine, and thioguanine. Thiopurines are commonly used drugs to treat acute lymphoblastic leukemia (ALL), autoimmune diseases, and inflammatory bowel disease (IBD), or to prevent rejection after organ transplant.1 Variants in TPMT and NUDT15 are associated with increased risk of life-threatening myelosuppression induced by thiopurines.1,2,3
Whereas TPMT variants are primarily found in those of European descent, genetic variants in NUDT15 are found in many populations (Figure 1).2
One genetic variant of CEP72 has been associated with vincristine-related peripheral neuropathy. Thus, genotyping of CEP72 is recommended to guide safer dosing of vincristine.4
Learn how TPMT and NUDT15 PGx reduces thiopurines-related ADRs.